Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations in psychosis

Behavioral and Brain Functions

Volumn 10, Issue 1, 2014, Pages

  Andreou, Dimitrios ^a   Söderman, Erik ^a   Axelsson, Tomas ^b   Sedvall, Göran C ^a   Terenius, Lars ^a   Agartz, Ingrid ^a,c,d   Jönsson, Erik G ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

^d DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

3 methoxy 4 hydroxyphenylglycol (MHPG); 5 hydroxyindoleacetic acid (5 HIAA); Cerebrospinal fluid; Homovanillic acid (HVA); Psychiatric genetics; Psychosis; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; HOMOVANILLIC ACID; MONOAMINE; NORADRENALIN; SEROTONIN; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE; BIOGENIC AMINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DISEASE ASSOCIATION; DNA DETERMINATION; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOAMINERGIC SYSTEM; PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; CEREBROSPINAL FLUID; GENETICS; GENOTYPE;

ADULT; BIOGENIC MONOAMINES; DOPAMINE; FEMALE; GENOTYPE; HUMANS; MALE; NOREPINEPHRINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; SEROTONIN;

EID: 84904778891     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-10-26     Document Type: Article

References (62)

1. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012, 13:537-551.
2. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, Kim Y, Lee SH, Magnusson PK, Sanchez N, Stahl EA, Williams S, Wray NR, Xia K, Bettella F, Borglum AD, Bulik-Sullivan BK, Cormican P, Craddock N, de Leeuw C, Durmishi N, Gill M, Golimbet V, Hamshere ML, Holmans P, Hougaard DM, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013, 45:1150-1159.
3. Moir AT, Ashcroft GW, Crawford TB, Eccleston D, Guldberg HC. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 1970, 93:357-368.
4. Nordin C, Siwers B, Bertilsson L. Site of lumbar puncture influences levels of monoamine metabolites. Arch Gen Psychiatry 1982, 39:1445.
5. Stanley M, Traskman-Bendz L, Dorovini-Zis K. Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 1985, 37:1279-1286.
6. Wester P, Bergstrom U, Eriksson A, Gezelius C, Hardy J, Winblad B. Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem 1990, 54:1148-1156.
7. Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals - a genetic study. J Psychiatr Res 1986, 20:19-29.
8. Rogers J, Martin LJ, Comuzzie AG, Mann JJ, Manuck SB, Leland M, Kaplan JR. Genetics of monoamine metabolites in baboons: overlapping sets of genes influence levels of 5-hydroxyindolacetic acid, 3-hydroxy-4-methoxyphenylglycol, and homovanillic acid. Biol Psychiatry 2004, 55:739-744.
9. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel F-A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985, 147:276-282.
10. Wieselgren IM, Lindstrom LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res 1998, 81:101-110.
11. Nikisch G, Baumann P, Wiedemann G, Kiessling B, Weisser H, Hertel A, Yoshitake T, Kehr J, Mathe AA. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol 2010, 30:496-503.
12. Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 2001, 25:468-475.
13. Cooper JR, Melcer I. The enzymic oxidation of tryptophan to 5-hydroxytryptophan in the biosynthesis of serotonin. J Pharmacol Exp Ther 1961, 132:265-268.
14. Nakamura K, Sugawara Y, Sawabe K, Ohashi A, Tsurui H, Xiu Y, Ohtsuji M, Lin QS, Nishimura H, Hasegawa H, Hirose S. Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci 2006, 26:530-534.
15. Flatmark T, Stevens RC. Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem Rev 1999, 99:2137-2160.
16. Sumi-Ichinose C, Ichinose H, Takahashi E, Hori T, Nagatsu T. Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic L-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry 1992, 31:2229-2238.
17. Kemper CM, O'Connor DT, Westlund KN. Immunocytochemical localization of dopamine-beta-hydroxylase in neurons of the human brain stem. Neuroscience 1987, 23:981-989.
18. Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, Seeman P, Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006, 31:2221-2230.
19. Sagud M, Muck-Seler D, Mihaljevic-Peles A, Vuksan-Cusa B, Zivkovic M, Jakovljevic M, Pivac N. Catechol-O-methyl transferase and schizophrenia. Psychiatr Danub 2010, 22:270-274.
20. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 1999, 22:197-217.
21. Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC. Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A 1991, 88:3637-3641.
22. Carlborg A, Jokinen J, Nordstro¨m A-L, Jo¨nsson EG, Nordstro¨m P. CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis. Schizophr Res 2009, 112:80-85.
23. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P) 1988, New York: Biometrics Research Department, New York State Psychiatric Institute.
24. Vares M, Ekholm A, Sedvall GC, Hall H, Jo¨nsson EG. Characterisation of patients with schizophrenia and related psychosis: evaluation of different diagnostic procedures. Psychopathology 2006, 39:286-295.
25. Ekholm B, Ekholm A, Adolfsson R, Vares M, O¨sby U, Sedvall GC, Jo¨nsson EG. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 2005, 59:457-464.
26. Jonsson EG, Bah J, Melke J, Abou Jamra R, Schumacher J, Westberg L, Ivo R, Cichon S, Propping P, Nothen MM, Eriksson E, Sedvall GC. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 2004, 4:4.
27. Swahn C-G, Sandga¨rde B, Wiesel F-A, Sedvall G. Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology (Berl) 1976, 48:147-152.
28. Geijer T, Neiman J, Rydberg U, Gyllander A, Jo¨nsson E, Sedvall G, Valverius P, Terenius L. Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur Arch Psychiatry Clin Neurosci 1994, 244:26-32.
29. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL, Hansen M, Steemers F, Butler SL, Deloukas P, Galver L, Hunt S, McBride C, Bibikova M, Rubano T, Chen J, Wickham E, Doucet D, Chang W, Campbell D, Zhang B, Kruglyak S, Bentley D, Haas J, Rigault P, Zhou L, Stuelpnagel J, Chee MS. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003, 68:69-78.
30. Rothman KJ. Six persistent research misconceptions. J Gen Intern Med 2014, 29:1060-1064.
31. Wang J, Shete S. Testing departure from Hardy-Weinberg proportions. Methods Mol Biol 2012, 850:77-102.
32. Zhang C, Li Z, Shao Y, Xie B, Du Y, Fang Y, Yu S. Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci 2011, 43:406-411.
33. Jo¨nsson E, Sedvall G, Brene´ S, Gustavsson JP, Geijer T, Terenius L, Crocq M-A, Lannfelt L, Tylec A, Sokoloff P, Schwartz JC, Wiesel F-A. Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry 1996, 40:1032-1043.
34. Rao F, Zhang K, Zhang L, Rana BK, Wessel J, Fung MM, Rodriguez-Flores JL, Taupenot L, Ziegler MG, O'Connor DT. Human tyrosine hydroxylase natural allelic variation: influence on autonomic function and hypertension. Cell Mol Neurobiol 2010, 30:1391-1394.
35. Fukuda S, Horiguchi M, Yamaguti K, Nakatomi Y, Kuratsune H, Ichinose H, Watanabe Y. Association of monoamine-synthesizing genes with the depression tendency and personality in chronic fatigue syndrome patients. Life Sci 2013, 92:183-186.
36. Sadahiro R, Suzuki A, Shibuya N, Kamata M, Matsumoto Y, Goto K, Otani K. Association study between a functional polymorphism of tyrosine hydroxylase gene promoter and personality traits in healthy subjects. Behav Brain Res 2010, 208:209-212.
37. Børglum AD, Hampson M, Kjeldsen TE, Muir W, Murray V, Ewald H, Mors O, Blackwood D, Kruse TA. Dopa decarboxylase genotypes may influence age at onset of schizophrenia. Mol Psychiatry 2001, 6:712-717.
38. Hyland K, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem 1992, 38:2405-2410.
39. Brautigam C, Hyland K, Wevers R, Sharma R, Wagner L, Stock GJ, Heitmann F, Hoffmann GF. Clinical and laboratory findings in twins with neonatal epileptic encephalopathy mimicking aromatic L-amino acid decarboxylase deficiency. Neuropediatrics 2002, 33:113-117.
40. Toma C, Hervas A, Balmana N, Salgado M, Maristany M, Vilella E, Aguilera F, Orejuela C, Cusco I, Gallastegui F, Perez-Jurado LA, Caballero-Andaluz R, Diego-Otero YD, Guzman-Alvarez G, Ramos-Quiroga JA, Ribases M, Bayes M, Cormand B. Neurotransmitter systems and neurotrophic factors in autism: association study of 37 genes suggests involvement of DDC. World J Biol Psychiatry 2012, 14:516-527.
41. Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 2001, 68:515-522.
42. Tang Y, Anderson GM, Zabetian CP, Kohnke MD, Cubells JF. Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+1603C - >T) with plasma dopamine beta-hydroxylase activity. Am J Med Genet B Neuropsychiatr Genet 2005, 139B:88-90.
43. Kwon HJ, Lim MH. Association between dopamine Beta-hydroxylase gene polymorphisms and attention-deficit hyperactivity disorder in korean children. Genet Test Mol Biomarkers 2013, 17:529-534.
44. Hess C, Reif A, Strobel A, Boreatti-Hummer A, Heine M, Lesch KP, Jacob CP. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm 2009, 116:121-130.
45. Preuss UW, Wurst FM, Ridinger M, Rujescu D, Fehr C, Koller G, Bondy B, Wodarz N, Soyka M, Zill P. Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: Results from a large multicenter association study. Drug Alcohol Depend 2013, 133:459-467.
46. Kukshal P, Kodavali VC, Srivastava V, Wood J, McClain L, Bhatia T, Bhagwat AM, Deshpande SN, Nimgaonkar VL, Thelma BK. Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort. J Psychiatr Res 2013, 47:1615-1622.
47. Ates O, Celikel FC, Taycan SE, Sezer S, Karakus N. Association between 1603C > T polymorphism of DBH gene and bipolar disorder in a Turkish population. Gene 2013, 519:356-359.
48. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997, 247:297-302.
49. Zalsman G, Huang YY, Harkavy-Friedman JM, Oquendo MA, Ellis SP, Mann JJ. Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of caucasians: A preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005, 132B:100-103.
50. Voisey J, Swagell CD, Hughes IP, Lawford BR, Young RM, Morris CP. HapMap tag-SNP analysis confirms a role for COMT in schizophrenia risk and reveals a novel association. Eur Psychiatry 2012, 27:372-376.
51. Voisey J, Swagell CD, Hughes IP, Lawford BR, Young RM, Morris CP. A novel SNP in COMT is associated with alcohol dependence but not opiate or nicotine dependence: a case control study. Behav Brain Funct 2011, 7:51.
52. Aklillu E, Karlsson S, Zachrisson OO, Ozdemir V, Agren H. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet Genomics 2009, 19:267-275.
53. Ducci F, Newman TK, Funt S, Brown GL, Virkkunen M, Goldman D. A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index. Mol Psychiatry 2006, 11:858-866.
54. Jonsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC. A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000, 34:239-244.
55. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, Kuhn CM, Lewis JG, Schanberg SM, Stafford-Smith M, Suarez EC, Clary GL, Svenson IK, Siegler IC. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 2003, 28:533-541.
56. Carrera N, Sanjuan J, Molto MD, Carracedo A, Costas J. Recent adaptive selection at MAOB and ancestral susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:369-374.
57. Mas S, Bernardo M, Parellada E, Garcia-Rizo C, Gasso P, Alvarez S, Lafuente A. ARVCF single marker and haplotypic association with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1064-1069.
58. Costa-Mallen P, Kelada SN, Costa LG, Checkoway H. Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene. Neurosci Lett 2005, 383:171-175.
59. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002, 110:1-7.
60. Gasso P, Bernardo M, Mas S, Crescenti A, Garcia C, Parellada E, Lafuente A. Association of A/G polymorphism in intron 13 of the monoamine oxidase B gene with schizophrenia in a Spanish population. Neuropsychobiology 2008, 58:65-70.
61. Dlugos AM, Palmer AA, de Wit H. Negative emotionality: monoamine oxidase B gene variants modulate personality traits in healthy humans. J Neural Transm 2009, 116:1323-1334.
62. Geracioti TD, West SA, Baker DG, Hill KK, Ekhator NN, Wortman MD, Keck PE, Norman AB. Low CSF concentration of a dopamine metabolite in tobacco smokers. Am J Psychiatry 1999, 156:130-132.